<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29787800</PMID><DateCompleted><Year>2018</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3441</ISSN><JournalIssue CitedMedium="Internet"><Volume>129</Volume><PubDate><Year>2018</Year><Month>Aug</Month></PubDate></JournalIssue><Title>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</Title><ISOAbbreviation>Eur J Pharm Biopharm</ISOAbbreviation></Journal><ArticleTitle>The effect of formulation on spray dried Sabin inactivated polio vaccine.</ArticleTitle><Pagination><StartPage>21</StartPage><EndPage>29</EndPage><MedlinePgn>21-29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejpb.2018.05.021</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0939-6411(18)30196-6</ELocationID><Abstract><AbstractText>The objective of this study was to develop a stable spray dried formulation, containing the three serotypes of Sabin inactivated polio vaccine (sIPV), aiming for minimal loss of native conformation (D-antigen) during drying and subsequent storage. The influence of atomization and drying stress during spray drying on trivalent sIPV was investigated. This was followed by excipient screening, in which monovalent sIPV was formulated and spray dried. Excipient combinations and concentrations were tailored to maximize both the antigen recovery of respective sIPV serotypes after spray drying and storage (T&#x202f;=&#x202f;40&#x202f;&#xb0;C and t&#x202f;=&#x202f;7&#x202f;days). Furthermore, a fractional factorial design was developed around the most promising formulations to elucidate the contribution of each excipient in stabilizing D-antigen during drying. Serotype 1 and 2 could be dried with 98% and 97% recovery, respectively. When subsequently stored at 40&#x202f;&#xb0;C for 7&#x202f;days, the D-antigenicity of serotype 1 was fully retained. For serotype 2 the D-antigenicity dropped to 71%. Serotype 3 was more challenging to stabilize and a recovery of 56% was attained after drying, followed by a further loss of 37% after storage at 40&#x202f;&#xb0;C for 7&#x202f;days. Further studies using a design of experiments approach demonstrated that trehalose/monosodium glutamate and maltodextrin/arginine combinations were crucial for stabilizing serotype 1 and 2, respectively. For sIPV serotype 3, the best formulation contained Medium199, glutathione and maltodextrin. For the trivalent vaccine it is therefore probably necessary to spray dry the different serotypes separately and mix the dry powders afterwards to obtain the trivalent vaccine.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kanojia</LastName><ForeName>Gaurav</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Intravacc (Institute for Translational Vaccinology), Bilthoven, The Netherlands; University of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Groningen, The Netherlands. Electronic address: gaurav.kanojia@intravacc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ten Have</LastName><ForeName>Rimko</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Intravacc (Institute for Translational Vaccinology), Bilthoven, The Netherlands. Electronic address: rimko.ten.have@intravacc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brugmans</LastName><ForeName>Debbie</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Intravacc (Institute for Translational Vaccinology), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soema</LastName><ForeName>Peter C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Intravacc (Institute for Translational Vaccinology), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frijlink</LastName><ForeName>Henderik W</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>University of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amorij</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Intravacc (Institute for Translational Vaccinology), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kersten</LastName><ForeName>Gideon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Intravacc (Institute for Translational Vaccinology), Bilthoven, The Netherlands; Division of Drug Delivery Technology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur J Pharm Biopharm</MedlineTA><NlmUniqueID>9109778</NlmUniqueID><ISSNLinking>0939-6411</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005079">Excipients</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011208">Powders</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003890" MajorTopicYN="N">Desiccation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004355" MajorTopicYN="N">Drug Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005079" MajorTopicYN="N">Excipients</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011208" MajorTopicYN="N">Powders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atomization stress and dry powder</Keyword><Keyword MajorTopicYN="N">D-antigen recovery</Keyword><Keyword MajorTopicYN="N">Polio vaccine</Keyword><Keyword MajorTopicYN="N">Spray drying</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29787800</ArticleId><ArticleId IdType="doi">10.1016/j.ejpb.2018.05.021</ArticleId><ArticleId IdType="pii">S0939-6411(18)30196-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>